Heron Therapeutics | HRTX - Gross Profit On Sales


Heron Therapeutics reported $29.47M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
ALKERMES USD 331.33M 7M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amarin USD 23.17M 961K Dec/2025
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Eisai JPY 168.85B 17.02B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 217.69M 106.25M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Merck USD 10.85B 2.57B Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 126.64M 15.61M Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Surmodics USD 20.08M 31.62M Jun/2025
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Veracyte USD 101.97M 10.69M Dec/2025
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026